Clinical Considerations for Immuno-oncology (IO) Sequencing in Advanced Endometrial Cancer

Panelists discuss how immune-oncology therapies and biomarkers like TMB, MSI, and HER2 are shaping treatment strategies and decision-making in advanced endometrial cancer, highlighting the need for further research and improved sequencing approaches.

EP. 1: Overview of Current Treatment Landscape of Advanced Endometrial Cancer

March 31st 2025

Panelists discuss how the integration of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and combination therapies, is transforming the treatment landscape of advanced endometrial cancer (EC), with a focus on biomarker-driven approaches and the ongoing role of chemotherapy.

EP. 2: Optimizing Management Strategies for Advanced Endometrial Cancer Progression After IO-Chemo

March 31st 2025

Panelists discuss how treating patients with advanced endometrial cancer (EC) who progress after immune-oncology (IO)-chemotherapy involves reassessing tumor biomarkers, considering alternative immunotherapies or targeted treatments, and personalizing care based on prior treatment responses and individual patient factors.

EP. 3: Key Factors Influencing IO Continuation or Discontinuation in Subsequent Lines of Treatment in Advanced EC

April 7th 2025

Panelists discuss how the decision to continue or discontinue immune-oncology (IO) therapy in subsequent lines of treatment for advanced endometrial cancer (EC) is influenced by factors such as tumor response, biomarker status, treatment tolerability, patient health, and the availability of alternative therapies.

EP. 4: Guiding Treatment Decisions Post-IO in Advanced EC: Insights from Available Data

April 7th 2025

Panelists discuss how treatment decisions for advanced endometrial cancer (EC) patients after progressing on immune-oncology (IO) therapy are guided by clinical trial data, real-world evidence, biomarker status, initial therapy response, and patient-specific factors to personalize subsequent treatment strategies.